Efficacy Observation on Recombinant Human Ad-p53 Injection Combined with Cisplatin for Malignant Pleural Effusion of Non-small-cell Lung Cancer with Intracavitary Administration / 中国药房

ABSTRACT

OBJECTIVE: To evaluate the efficacy and safety of recombinant human Ad-p53 injection (rAd-p53) combined with cisplatin in the treatment of malignant pleural effusions of non-small-cell lung cancer (NSCLC). METHODS: 46 patients with malignant pleural effusions of NSCLC were randomly divided into groupⅠ, Ⅱand Ⅲ. The groups were given cisplatin, rAd-p53 and combination medication, respectively once a week. The efficacy and quality of life were evaluated after 4 weeks. RESULTS: There were significant difference in among three groups in effective rate and improvement rate of life quality (P0.05). CONCLUSION: rAd-p53 combined with cisplatin has sound effect on malignant pleural effusions of NSCLC without aggravating effect on the toxicity of chemotherapy, which is worth of spreading in the clinic.